HC Wainwright resumed coverage of Exicure with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2021 | $2.25 → $0.40 | Buy → Neutral | Chardan Capital Markets |
| 11/23/2021 | $7.00 → $2.25 | Buy | Chardan Capital |
4 - EXICURE, INC. (0001698530) (Issuer)
Exicure, Inc. (NASDAQ:XCUR, the ", Company", )) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Equity Financing In an agreement dated November 6, 2024 and executed on November 12, 2024, the Company agreed to sell and issue to HiTron Systems Inc. ("HiTron") 433,333 shares of common stock, par value $0.0001 per share, for $1.3 million, at
Exicure, Inc. (NASDAQ:XCUR, the ", Company", ))), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Second Quarter 2024 Financial Results Cash Position: Cash and cash equivalents were $0.5 million as of June 30, 2024, as compared to $0.8 million as of December 31, 2023. The Company believes that its cash and cash equivalents are insufficie
Exicure, Inc. (NASDAQ:XCUR, the "Company"))), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. First Quarter 2024 Financial Results Cash Position: Cash and cash equivalents were $0.4 million as of March 31, 2024, as compared to $0.8 million as of December 31, 2023. Subsequent to March 31, 2024, our cash and cash equivalents have decreased
SC 13D/A - EXICURE, INC. (0001698530) (Subject)
SC 13D/A - EXICURE, INC. (0001698530) (Subject)
SC 13D/A - EXICURE, INC. (0001698530) (Subject)
Chardan Capital Markets downgraded Exicure from Buy to Neutral and set a new price target of $0.40 from $2.25 previously
Chardan Capital reiterated coverage of Exicure with a rating of Buy and set a new price target of $2.25 from $7.00 previously
HC Wainwright & Co. reiterated coverage of Exicure with a rating of Buy and set a new price target of $6.00 from $8.00 previously
PRE 14A - EXICURE, INC. (0001698530) (Filer)
8-K - EXICURE, INC. (0001698530) (Filer)
10-Q - EXICURE, INC. (0001698530) (Filer)
4 - EXICURE, INC. (0001698530) (Issuer)
4 - EXICURE, INC. (0001698530) (Issuer)
4 - EXICURE, INC. (0001698530) (Issuer)
Exicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief Financial Officer of the Company. Mr. Kang and Ms. Hwang succeed Mr. Jung-Sang (Michael) Kim, who stepped down as Chief Executive Officer and Chief Financial Officer last Friday. Additionally, effective as of August 21, 2023, the Board also approved the appointment of Hyuk Joon (Raymond) Ko as a Class III direct
Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). The Company today announced that the Board fully supports the strategic vision of Mr. Kim and his ongoing efforts to maximize stockholder v
Exicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of April 26, 2023, Jung-Sang (Michael) Kim was appointed as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). Mr. Kim succeeds Dr. Matthias Schroff, who yesterday stepped down as Chief Executive Officer and a Class I member of the Board, and Mr. Elias D. Papadimas, who yesterday stepped down as our Chief Financial Officer. Effective as of April 26, 2023, the Board also approved the appointme
Exicure, Inc. (NASDAQ:XCUR, the ", Company", )) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. Equity Financing In an agreement dated November 6, 2024 and executed on November 12, 2024, the Company agreed to sell and issue to HiTron Systems Inc. ("HiTron") 433,333 shares of common stock, par value $0.0001 per share, for $1.3 million, at
Exicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel ("Panel") granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure the Company's continued listing on Nasdaq. As previously announced, the Company has regained compliance with Nasdaq's minimum bid price requirement and exchanged approximately $1,000,000 of indebtedness for equity at a conver
Exicure, Inc. (NASDAQ:XCUR, "the Company"))) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock will continue to trade on the NASDAQ Capital Market under the symbol "XCUR". The Reverse Stock Split is an effort to regain compliance with Nasdaq's listing rules. The Reverse Stock Split was approved by the Company's stock
Shares of Comcast Corporation (NASDAQ:CMCSA) fell sharply during Tuesday's session after the company reported worse-than-expected second-quarter sales results. Comcast reported second-quarter revenue decline of 2.7% year-over-year to $29.69 billion, missing the analyst consensus estimate of $30.02 billion.The company reported adjusted EPS of $1.21, beating analyst consensus estimates of $1.12, according to data from Benzinga Pro. Comcast shares declined 6.1% to $37.12 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Azitra, Inc. (NYSE:AZTR) shares jumped 529% to $10.19 after the company announced that the U.S. Patent and Trademark Office grant